NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free AXGN Stock Alerts $5.83 +0.16 (+2.82%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$5.66▼$6.0050-Day Range$5.67▼$10.6952-Week Range$3.45▼$10.83Volume356,614 shsAverage Volume400,408 shsMarket Capitalization$254.83 millionP/E RatioN/ADividend YieldN/APrice Target$10.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AxoGen alerts: Email Address AxoGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside83.0% Upside$10.67 Price TargetShort InterestHealthy4.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.07Based on 11 Articles This WeekInsider TradingSelling Shares$928,054 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.46) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector459th out of 903 stocksElectromedical Equipment Industry8th out of 20 stocks 3.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has received no research coverage in the past 90 days.Read more about AxoGen's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.11% of the float of AxoGen has been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in AxoGen has recently decreased by 3.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 1.6 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for AxoGen this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $928,054.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.46) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -11.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -11.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 2.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About AxoGen Stock (NASDAQ:AXGN)AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesMay 7, 2024 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Downgraded to Hold at StockNews.comMay 6, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call TranscriptMay 8, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 3, 2024 | finance.yahoo.comAxoGen First Quarter 2024 Earnings: Misses ExpectationsMay 3, 2024 | finance.yahoo.comAxogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst ChallengesMay 2, 2024 | msn.comAxoGen Non-GAAP EPS of -$0.06 beats by $0.01, revenue of $41.4M misses by $0.65MMay 2, 2024 | globenewswire.comAxogen, Inc Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comHere's what Wall Street expects from AxoGen's earnings reportMay 8, 2024 | Crypto 101 Media (Ad)Elon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.May 1, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) is largely controlled by institutional shareholders who own 58% of the companyApril 30, 2024 | finanznachrichten.deAxogen, Inc.: Axogen Announces First Surgical Implants of Avive+ Soft Tissue MatrixApril 29, 2024 | globenewswire.comAxogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™April 16, 2024 | globenewswire.comAxogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024April 4, 2024 | finance.yahoo.comAnalysts Expect Breakeven For AxoGen, Inc. (NASDAQ:AXGN) Before LongMarch 9, 2024 | finance.yahoo.comDirector Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN)March 8, 2024 | finance.yahoo.comUS$13.80 - That's What Analysts Think AxoGen, Inc. (NASDAQ:AXGN) Is Worth After These ResultsMarch 7, 2024 | seekingalpha.comAxoGen, Inc. (AXGN) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | markets.businessinsider.comAxogen’s Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price TargetMarch 6, 2024 | sg.finance.yahoo.comAxoGen, Inc. (AXGN) stock price, news, quote & history – Yahoo FinanceMarch 6, 2024 | finanznachrichten.deAxogen, Inc.: Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial ResultsMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed: AxoGen’s Robust Growth and Market Potential Drive Positive OutlookMarch 6, 2024 | msn.comAxoGen files $100M mixed securities shelfMarch 6, 2024 | finance.yahoo.comAxoGen Full Year 2023 Earnings: Beats ExpectationsMarch 6, 2024 | finance.yahoo.comAxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call TranscriptMarch 5, 2024 | investing.comAxogen Inc (AXGN) Earnings Dates & ReportsMarch 5, 2024 | msn.comAxoGen Non-GAAP EPS of -$0.06 beats by $0.02, revenue of $42.9M beats by $1.9MMarch 5, 2024 | finance.yahoo.comAxogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023See More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/07/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees426Year FoundedN/APrice Target and Rating Average Stock Price Target$10.67 High Stock Price Target$12.00 Low Stock Price Target$9.00 Potential Upside/Downside+83.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,720,000.00 Net Margins-12.99% Pretax Margin-12.99% Return on Equity-22.18% Return on Assets-11.06% Debt Debt-to-Equity Ratio0.72 Current Ratio3.43 Quick Ratio2.23 Sales & Book Value Annual Sales$159.01 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book2.63Miscellaneous Outstanding Shares43,710,000Free Float40,646,000Market Cap$254.83 million OptionableOptionable Beta1.07 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 62)Chairman, President & CEO Comp: $1.49MMr. Erick DeVinney (Age 48)Chief Innovation Officer Comp: $557.9kMr. Harold D. TamayoVice President of Finance & Investor RelationsMr. Marc A. Began (Age 56)Executive VP, General Counsel & Chief Compliance Officer Ms. Doris QuackenbushVice President of SalesMr. Jens Schroeder KempChief Marketing OfficerDr. Ivica Ducic M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsEdap TmsNASDAQ:EDAPSemler ScientificNASDAQ:SMLROutset MedicalNASDAQ:OMZynexNASDAQ:ZYXIElectromedNYSE:ELMDView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 1,651 shares on 5/1/2024Ownership: 0.048%Rice Hall James & Associates LLCBought 153,174 shares on 4/23/2024Ownership: 0.351%Karen L ZaderejSold 39,280 sharesTotal: $301,670.40 ($7.68/share)Erick Wayne DevinneySold 4,578 sharesTotal: $35,159.04 ($7.68/share)Michael Patrick DonovanSold 6,033 sharesTotal: $46,333.44 ($7.68/share)View All Insider TransactionsView All Institutional Transactions AXGN Stock Analysis - Frequently Asked Questions Should I buy or sell AxoGen stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXGN shares. View AXGN analyst ratings or view top-rated stocks. What is AxoGen's stock price target for 2024? 3 analysts have issued 1-year target prices for AxoGen's shares. Their AXGN share price targets range from $9.00 to $12.00. On average, they expect the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 83.0% from the stock's current price. View analysts price targets for AXGN or view top-rated stocks among Wall Street analysts. How have AXGN shares performed in 2024? AxoGen's stock was trading at $6.83 on January 1st, 2024. Since then, AXGN shares have decreased by 14.6% and is now trading at $5.83. View the best growth stocks for 2024 here. When is AxoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our AXGN earnings forecast. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) announced its earnings results on Tuesday, March, 5th. The medical equipment provider reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.11. The medical equipment provider had revenue of $42.92 million for the quarter, compared to analyst estimates of $42.70 million. AxoGen had a negative trailing twelve-month return on equity of 22.18% and a negative net margin of 12.99%. What ETF holds AxoGen's stock? iShares Neuroscience and Healthcare ETF holds 2,930 shares of AXGN stock, representing 0.56% of its portfolio. What guidance has AxoGen issued on next quarter's earnings? AxoGen issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $177.0 million-$181.0 million, compared to the consensus revenue estimate of $179.5 million. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL), NVIDIA (NVDA) and Fossil Group (FOSL). Who are AxoGen's major shareholders? AxoGen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.35%), BNP Paribas Financial Markets (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amy Mcbride Wendell, Erick Wayne Devinney, Gregory Gene Freitag, Guido J Neels, Karen L Zaderej, Maria D Martinez, Michael Patrick Donovan, Peter J Mariani and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AXGN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsThe AI Stock that’s Disrupting Every IndustryStockEarningsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
